TITAN PHARMACEUTICALS INC — Director's Dealing 2019

Apr 3, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TITAN PHARMACEUTICALS INC (TTNP)
CIK: 0000910267
Period of Report: 2019-04-02

Reporting Person: BHONSLE SUNIL (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-04-02	Option to Purchase Common Stock	$1.75	A	200000	Acquired	2029-04-02	Common Stock (200000)	Direct

Footnotes

F1: The options vest as to 83,334 shares on the grant date with the balance to vest at such time, if ever, as the Company receives shareholder approval of the Board's amendment to Section 5.1 of the Company's option plan to increase the limitation on the number of awards granted to a single individual in any calendar year from 83,334 to 250,000.